Valuation: Protalix BioTherapeutics, Inc.

Market Cap 222M 196M 186M 168M 316M 21.32B 320M 2.22B 854M 10.9B 835M 817M 34.95B P/E 2026 *
11.5x
P/E 2027 * 55.2x
Enterprise Value 222M 196M 186M 168M 316M 21.32B 320M 2.22B 854M 10.9B 835M 817M 34.95B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 3.35x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day+2.60%
1 week-1.43%
1 month+7.39%
3 months+18.45%
6 months+27.19%
Current year+53.33%
1 week 2.61
Extreme 2.61
2.82
1 month 2.57
Extreme 2.57
2.85
Current year 1.72
Extreme 1.72
3.19
1 year 1.6
Extreme 1.6
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Director

25,500 0.0316%
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

480,000 0.5957%
Change 5-day change 1-year change 3-year change Capi.($)
+2.60%-1.43%+24.32%+66.27% 222M
-2.33%+0.53%+51.65%+115.42% 1,031B
-1.06%-1.65%+42.78%+69.98% 638B
-0.65%-1.32%+12.98%+75.49% 462B
-2.66%-1.87%+73.13%+41.15% 359B
+0.53%-3.25%+24.55%+41.75% 335B
-0.80%+0.24%+14.63%+27.71% 273B
-1.06%-1.87%-2.16%+11.12% 253B
-0.50%+3.80%+49.37%+56.84% 228B
-1.47%-1.53%+34.28%+98.89% 185B
Average +0.55%-0.86%+32.55%+60.46% 376.41B
Weighted average by Cap. +0.40%-0.35%+37.74%+71.45%

Financials

2026 *2027 *
Net sales 82.16M 72.35M 68.55M 61.88M 117M 7.88B 118M 820M 316M 4.03B 309M 302M 12.91B 66.48M 58.54M 55.47M 50.07M 94.38M 6.37B 95.6M 664M 255M 3.26B 250M 244M 10.45B
Net income 19.63M 17.29M 16.38M 14.79M 27.87M 1.88B 28.23M 196M 75.42M 962M 73.72M 72.11M 3.09B 3.79M 3.34M 3.17M 2.86M 5.39M 364M 5.46M 37.87M 14.57M 186M 14.25M 13.94M 596M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
30/09/26 $2.760 +2.60% 836,259
29/09/26 $2.690 -.--% 898,556
28/09/26 $2.690 -1.10% 832,815
25/09/26 $2.720 -1.09% 386,025
24/09/26 $2.750 -1.79% 302,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.760USD
Average target price
11.00USD
Spread / Average Target
+298.55%

Quarterly revenue - Rate of surprise